Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study

Author:

Pellegrini Ilaria,Drabbe Cas,Grünhagen Dirk J.ORCID,Van de Sande Michiel A. J.ORCID,de Haan Jacco J.ORCID,Keymeulen Kristien B.M.I.,Bonenkamp Johannes J.,Van der Graaf Winette T. A.ORCID,Husson OlgaORCID

Abstract

Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care. Methods: A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care. Results: In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22–2.25; p = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07–2.05; p = 0.017) and 1.4 (95% CI 1.06–1.98; p = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20–2.61; p = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 p ≤ 0.001). Conclusions: Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.

Funder

Netherlands Organization for Scientific Research

Social Psychology Fellowship from the Dutch Cancer Society

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference43 articles.

1. WHO Classification of Tumours (2020). WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours, IARC. [5th ed.]. Available online: https://publications.iarc.fr/588.

2. Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet-a population-based study;Gatta;Lancet Oncol.,2017

3. Sarcoma treatment in the era of molecular medicine;Alonso;EMBO Mol. Med.,2020

4. Burden of soft-tissue and bone sarcoma in routine care: Estimation of incidence, prevalence and survival for health services research;Trautmann;Cancer Epidemiol.,2015

5. Improved survival using specialized multidisciplinary board in sarcoma patients;Blay;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2017

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3